Hims & Hers prices $350 million convertible notes offering

Hims & Hers is raising $350 million in 0.00% convertible senior notes due 2032, up from the prior $300 million target, with an initial conversion price of about $29.53 per share and a capped call designed to reduce dilution. The deal supports international expansion, technology and fulfillment investment, and the proposed Eucalyptus acquisition, but it also follows a first-quarter 2026 earnings miss of -$0.40 EPS versus $0.01 expected and revenue of $608 million versus $616.5 million expected. BofA lowered its price target to $28 from $30 while keeping a Neutral rating.

Analysis

This financing is less about funding growth and more about buying time against a credibility reset. A zero-coupon convert at a meaningful premium means the company is effectively issuing equity with delayed dilution, which usually signals management prefers to monetize upside volatility now rather than rely on operating cash generation over the next 12-18 months. The enlarged size suggests the balance sheet is being pre-funded for an acquisition/integration window, but it also tells you equity investors are being asked to underwrite execution risk before the core business has re-accelerated.

The second-order issue is that capped-call protection pushes the dilution problem out, not away: if the stock grinds higher into the cap zone, existing holders face a more complex overhang where upside is partially transferred to option counterparties. That structure often compresses near-term upside in the common because convert buyers and hedgers can dampen volatility once the deal is digested. For competitors, this is a mixed signal: if the spend is genuinely focused on AI, fulfillment, and international rollout, smaller telehealth players may face a stronger scale advantage in customer acquisition and logistics, but if integration distracts management, rivals with cleaner execution can steal share during the next two quarters.

The key catalyst path is not the bond itself; it is whether the next 1-2 earnings prints show margin stabilization and improved cohort economics. If those metrics do not improve by mid-2026, the market will likely reprice the financing as a bridge to more dilution, especially if acquisition synergies arrive late. The contrarian view is that sentiment may already be too bearish: with the stock near fair value and the deal monetizing upside at a 32% conversion premium, downside from the financing alone may be limited unless fundamentals deteriorate again. The real trade is on execution optionality, not on the notes.

Key Decisions for Investors

• Short-dated tactical: buy HIMS puts or put spreads into the post-deal digestion window (2-6 weeks) to express concern that hedging flow and financing overhang cap upside near term; target ~1.5-2.5x payoff if the stock mean-reverts back toward pre-deal levels.
• Medium-term: pair long a cleaner telehealth/healthcare tech operator versus short HIMS over the next 1-2 quarters to isolate execution risk from sector exposure; the thesis is that HIMS must prove integration and margin repair before the market re-rates the growth story.
• If you want upside exposure, use call spreads rather than stock and size for a 3-6 month horizon; the capped-call structure suggests convexity above the mid-$30s could be muted, so avoid paying for open-ended upside.
• Monitor Q2/Q3 cohort and EBITDA trends closely; if gross margin and contribution margin inflect, cover any short exposure quickly because the market will likely reframe the convert as financing flexibility rather than distress.